A milk protein that binds iron tightly, shifting it out of storage and denying it to bacteria at body surfaces. Strongest evidence: helping antibiotics clear the stomach bacterium behind ulcers. Weaker signals for stomach and bowel upset, abdominal fat, skin and gums. Against a standard iron tablet it offers gentler digestion, not better numbers. Ageing claims rest on animal work. (Full Review)

Protocol

Standard dose range

100–200 mg daily for iron status

200–600 mg daily for immune and inflammatory endpoints; 1.5–3 g daily in the colorectal polyp and oncology trials. Most consumer capsules supply 250–300 mg.

Best time of day

Fasted dosing

Typically 30–60 minutes before breakfast or at bedtime. Food proteins compete for pepsin and dietary calcium blunts the iron effect.

Single versus split dosing

Split at lower doses

Anemia protocols split the dose morning and evening; immune and visceral-fat trials used once-daily dosing successfully.

Time to effect

Visceral fat

8 weeks

Reduction in deep abdominal fat, with the enteric-coated form.

Gingival and acne endpoints

10–12 weeks

Gingival inflammation and plaque; inflammatory and non-inflammatory acne lesions.

Iron markers

4–12 weeks

Ferritin, transferrin saturation and hemoglobin shift across this window.

Benefits

High: Higher Helicobacter pylori eradication rates as an add-on to antibiotics

Medium: Reduction in visceral fat; reduction in acne lesion counts; improved gingival health and lower periodontal bacterial load; fewer episodes of acute gastrointestinal illness

Low: Correction of iron-deficiency anemia with better digestive tolerability; shorter and less frequent respiratory infections; slowed growth of small colorectal adenomas; improved bone turnover balance after menopause; relief of dry eye symptoms; fewer recurrences of vaginal infections; adjunctive antitumor activity

Speculative: Lower systemic inflammatory signalling; shift in gut bacterial composition; modulation of cellular senescence and longevity pathways

Contraindications

Diagnosed IgE-mediated cow's-milk allergy (bovine-derived products)

Hereditary hemochromatosis, particularly HFE C282Y homozygotes

Transferrin saturation above 45%, or ferritin above 300 ng/mL (men) or 200 ng/mL (women)

Transfusion-dependent thalassemia or other iron-loading anemias

Confirmed moderate-to-severe iron-deficiency anemia (hemoglobin below 10 g/dL) where used in place of iron salts

Key Interactions

Levothyroxine: separated by at least four hours

Tetracycline and fluoroquinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin): separated by at least two hours

Bisphosphonates (alendronate, risedronate, ibandronate): bisphosphonate on waking, lactoferrin later in the day

Levodopa and methyldopa: separated by at least two hours

Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole): monitor

Helicobacter pylori eradication regimens (clarithromycin, amoxicillin, plus a proton pump inhibitor): additive and intended, no dose change

Over-the-counter antacids containing calcium, magnesium, or aluminium: two-hour separation

Oral iron salts (ferrous sulfate, ferrous fumarate, ferrous bisglycinate): additive on iron status, iron markers require monitoring

Vitamin C and other iron-absorption enhancers: additive

Bovine colostrum supplements: additive, belongs in the daily total

Zinc and calcium supplements: caution on timing, separation to a different meal

Therapeutic phlebotomy or regular blood donation: caution, opposing goals

Risk & Side Effects

Medium: Under-treatment when substituted for standard iron therapy; allergic reaction in people with cow's-milk allergy

Low: Mild gastrointestinal symptoms; iron loading in people predisposed to iron overload

Speculative: Support for iron-scavenging pathogens; disruption of gut microbial balance at high doses

Monitoring

Marker	Target	Why
Ferritin	50–150 ng/mL (women); 50–200 ng/mL (men)	Primary target; reflects stored iron
Transferrin saturation (TSAT)	25–40%	Detects both depletion and the overload the intervention could worsen
Hemoglobin	13.5–15.0 g/dL (women); 14.5–16.5 g/dL (men)	Confirms whether depletion has progressed to anemia
Mean corpuscular volume (MCV)	85–92 fL	Average red cell size; falls before hemoglobin in developing deficiency
High-sensitivity C-reactive protein (hs-CRP)	Below 1.0 mg/L	General inflammation; the mechanism lactoferrin is proposed to act through
Total iron-binding capacity (TIBC)	250–370 µg/dL	How much iron the blood could carry; rises in depletion
Serum hepcidin	No established target range; direction of change from own baseline	The hormone the main proposed mechanism acts on

Cadence: Baseline panel before the first dose; ferritin, transferrin saturation and a complete blood count repeated at 8–12 weeks, then at six months, then every 6–12 months for continued use; inflammation markers repeated at 12 weeks.

Qualitative Assessment

Energy through the afternoon, and whether stairs or hills feel easier
Exercise capacity and heart-rate recovery, which respond early to iron repletion
Cold hands and feet, hair shedding, and brittle nails, all classic depletion signs
Digestive comfort compared with any previous iron supplement
Frequency and duration of upper respiratory illness across a season
Gum bleeding on brushing, and skin lesion counts where those were the reason for use

Lactoferrin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment